SFM
PCRX icon

Signet Financial Management’s Pacira BioSciences PCRX Stock Holding History

Signet Financial Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-608
Closed -$37K – 1014
2021
Q4 		$37K Buy
+608
New +$33.5K 0.01% 606

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Signet Financial Management's PCRX Position: Q1 2022 in Review

Signet Financial Management sold out of Pacira BioSciences (PCRX) in Q1 2022, closing a stake of 608 shares — an estimated $37K sold.

Signet Financial Management first reported a position in PCRX in Q4 2021 and held it in 1 quarter. The position peaked at $37K in Q4 2021. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

  • Signet Financial Management reported no remaining Pacira BioSciences position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 608 Pacira BioSciences shares in Q1 2022, an estimated $37K.
  • Signet Financial Management first reported a position in Pacira BioSciences in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's Pacira BioSciences position peaked at $37K in Q4 2021.
  • 301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.